Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013)

C. Gabay; P. Emery; R. van Vollenhoven

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013)

C. Gabay
, P. Emery
, R. van Vollenhoven

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Pages (from-to)	1540
Journal	Lancet
Volume	381
Issue number	9877
Publication status	Published - 2013

Cite this

@article{cc5cdc18f66f41578ed47a21bd1c0935,

title = "Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013)",

author = "C. Gabay and P. Emery and \{van Vollenhoven\}, R.",

year = "2013",

language = "English",

volume = "381",

pages = "1540",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9877",

}

TY - JOUR

T1 - Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial (vol 381, pg 1541, 2013)

AU - Gabay, C.

AU - Emery, P.

AU - van Vollenhoven, R.

PY - 2013

Y1 - 2013

M3 - Comment/Letter to the editor

SN - 0140-6736

VL - 381

SP - 1540

JO - Lancet

JF - Lancet

IS - 9877

ER -